Fibrobiologics LLC

Fibrobiologics LLC is a for-profit organization registered in the System for Award Management (SAM) since October 2016, with registration valid through December 2025. The company appears to be a biotechnology research firm focused on developing novel peptide-based therapeutic agents for treating fibrotic diseases, with a particular emphasis on developing targeted peptide treatments for challenging medical conditions involving tissue fibrosis and autoimmune disorders.

The company has received multiple federal grant awards from civilian health research agencies, specifically the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Heart, Lung, and Blood Institute (NHLBI). These grants, totaling approximately $605,813, have supported preclinical research and development of a peptide therapeutic called M10, designed to address fibrotic conditions such as systemic sclerosis (scleroderma) and idiopathic pulmonary fibrosis (IPF). The research projects involve determining the antifibrotic activity of M10 in primary human fibroblasts, evaluating its effectiveness in animal models, and assessing pharmacokinetic parameters, metabolism, biodistribution, and toxicity. Each grant has been a Project Grant under specific research programs, including the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) and the Cardiovascular Diseases Research program (CFDA 93.837), with performance periods ranging from 12-13 months and focusing on advancing potential new therapeutic approaches for severe, progressive fibrotic diseases.

FibroBiologics, LLC is a small business company focused on the development of novel treatment for pulmonary fibrosis and other pathological conditions including wound healing and skin fibrosis.